Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07
  • D-N-Acetylgalactosamine: Protocols for Brain Glycoprotein An

    2026-06-13

    D-N-Acetylgalactosamine: Technical Application for Brain Glycoprotein Research

    What This Product Solves

    D-N-Acetylgalactosamine (N-((3R,4R,5R,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide) is an endogenous metabolite and a critical constituent in brain heteropolysaccharides. Its primary value lies in enabling precise analysis of glycoprotein structure and glycosylation pathways in neurological research workflows. The compound’s high purity (≥98%), confirmed by HPLC and NMR, supports reproducibility in studies focusing on glycoprotein constituent characterization, neuronal signaling, and metabolism. Researchers rely on its solubility in water and DMSO for biochemical assays that interrogate glycoprotein function in brain tissue. The product is not recommended for applications involving ethanol-based protocols or workflows requiring long-term solution storage, which can compromise reliability.

    For a detailed technical overview, see D-N-Acetylgalactosamine: Technical Parameters for Brain Glycoproteins, which outlines assay compatibility and workflow considerations. Further practical guidance is available in D-N-Acetylgalactosamine: Practical Guidance for Brain Glycoprotein Research, focusing on reproducibility and procedural handling in neuronal studies.

    Protocol Parameters

    • Assay: Solubility in water
      Value: ≥22.1 mg/mL
      Applicability: Suitable for aqueous-based glycoprotein constituent assays and general biochemical workflows in neurological research.
      Rationale: Ensures consistent dissolution and reagent delivery for protocols investigating glycosylation and brain heteropolysaccharides.
      Source type: product information
    • Assay: Solubility in DMSO
      Value: ≥22.75 mg/mL
      Applicability: Suitable for protocols requiring DMSO as a solvent in glycoprotein structure analysis or compound screening involving neuronal cell models.
      Rationale: Supports flexibility in workflow design where organic solvent compatibility is required, provided ethanol is avoided.
      Source type: product information
    • Assay: Storage of powder and solutions
      Value: Store powder at -20°C; solutions not recommended for long-term storage
      Applicability: Powder stability is preserved for extended periods, but solutions should be prepared fresh for each use.
      Rationale: Prevents degradation and ensures reproducibility in glycoprotein and glycosylation pathway studies.
      Source type: product information
    • Assay: Purity verification
      Value: ≥98% (HPLC, NMR)
      Applicability: Supports quantitative and qualitative studies requiring minimal background interference.
      Rationale: High purity minimizes confounding variables during glycoprotein constituent analysis.
      Source type: product information

    Workflow Setup and QC Checklist

    • Pre-dissolution check: Verify that D-N-Acetylgalactosamine is fully equilibrated to room temperature prior to weighing, minimizing condensation risk.
    • Solvent selection: Use only water or DMSO as solvents. Ethanol should be strictly avoided due to insolubility, which can lead to precipitation and sample loss.
    • Solution preparation: Prepare solutions fresh immediately before use. Avoid storing working solutions, as stability is not guaranteed beyond a single day.
    • Concentration verification: Confirm complete dissolution visually and, if necessary, by gentle vortexing or brief sonication. Do not use solutions with visible particulates.
    • Storage: Store the dry product tightly sealed at -20°C. Avoid repeated freeze-thaw cycles. If aliquoting is required, do so under dry, cold conditions and use inert containers.
    • Documentation: Record lot number, preparation date, and storage conditions for traceability in glycosylation pathway and brain heteropolysaccharide analysis workflows.

    Common Failure Modes and Fixes

    • Incomplete dissolution in solvent: If undissolved material remains after mixing in water or DMSO, increase mixing time, apply gentle sonication, or slightly warm the solution (not exceeding 37°C). Do not attempt to dissolve in ethanol.
    • Loss of activity or degradation: If unexpected results occur, confirm the solution was freshly prepared and not stored. Discard any aged solutions and prepare a new batch from powder stored at -20°C.
    • Precipitation during assay setup: Check that the working concentration does not exceed solubility limits (22.1 mg/mL in water, 22.75 mg/mL in DMSO). Dilute as needed to fully dissolve the compound.
    • Sample contamination: Use only high-purity water or analytical-grade DMSO. Avoid cross-contamination from pipettes or containers previously used with incompatible solvents.

    Scope and Limitations

    D-N-Acetylgalactosamine is optimized for biochemical and neurological research requiring characterization of glycoprotein constituents in brain tissue. Its water and DMSO solubility support workflows in glycosylation pathway analysis and studies of neuronal signaling and metabolism. However, the product is incompatible with ethanol-based protocols and should not be used where long-term solution storage is necessary. Its intended use is limited to laboratory research applications; suitability for clinical or diagnostic workflows is not established. All handling recommendations are based on product technical data and established workflow best practices.

    Conclusion

    D-N-Acetylgalactosamine enables precise, reproducible interrogation of glycoprotein structure and glycosylation pathways in brain tissue research. By adhering to solubility, storage, and workflow parameters, researchers can minimize technical failures and ensure high data quality. For additional details or to order, consult the D-N-Acetylgalactosamine product page at APExBIO. Always verify protocol compatibility before integrating this reagent into new experimental designs.